Methods for the detection of soluble .beta.-amyloid peptide
First Claim
1. A method for detecting a soluble β
- -amyloid peptide (β
AP) in a fluid sample in the presence of β
-amyloid precursor protein (APP) or fragments thereof, said method comprising;
capturing soluble β
AP from the sample using a first binding substance under conditions in which the first specific binding substance binds to an epitope at a junction region on the β
AP and which is substantially free from cross-reactivity with APP and fragments thereof other than β
AP, wherein the junction region is centered at the site between β
AP amino acid residues 16 and 17 and is a target for normal proteolytic cleavage; and
detecting capture of the soluble β
AP using a labeled second binding substance which binds to an epitope on a second region of the soluble β
AP other than the epitope on the β
AP which is bound by the first binding substance.
1 Assignment
0 Petitions
Accused Products
Abstract
Soluble β-amyloid peptide (βAP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of βAP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of βAP in the animal or culture medium observed. It has been found that elevated levels of βAP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a βAP-related condition in a patient, such as Alzheimer'"'"'s Disease. Methods for diagnosing and monitoring βAP-related conditions comprise measuring the levels of βAP in such body fluids from a patient.
-
Citations
16 Claims
-
1. A method for detecting a soluble β
- -amyloid peptide (β
AP) in a fluid sample in the presence of β
-amyloid precursor protein (APP) or fragments thereof, said method comprising;capturing soluble β
AP from the sample using a first binding substance under conditions in which the first specific binding substance binds to an epitope at a junction region on the β
AP and which is substantially free from cross-reactivity with APP and fragments thereof other than β
AP, wherein the junction region is centered at the site between β
AP amino acid residues 16 and 17 and is a target for normal proteolytic cleavage; and
detecting capture of the soluble β
AP using a labeled second binding substance which binds to an epitope on a second region of the soluble β
AP other than the epitope on the β
AP which is bound by the first binding substance. - View Dependent Claims (2, 3, 4)
- -amyloid peptide (β
-
5. A method for detecting a soluble β
- -amyloid peptide (β
AP) in a fluid sample, said method comprising;exposing the sample to a first binding substance specific for an epitope at a junction region on soluble β
AP disposed between amino acid residues 13 to 28; anddetecting binding between the first binding substance and the soluble β
AP under conditions where the first binding substance binds to the β
AP without substantial cross-reactivity with β
-amyloid precursor protein (APP) and fragments thereof other than β
AP. - View Dependent Claims (6, 7, 8, 9, 10, 11)
- -amyloid peptide (β
-
12. A method for detecting a soluble β
- -amyloid peptide (β
AP) in a fluid sample which may contain β
AP and β
AP fragments as well as soluble fragments of β
-amyloid precursor protein (APP) other than β
AP, said method comprising;exposing the fluid sample to a first binding substance under conditions in which the first binding substance will bind to an epitope on soluble β
AP and β
AP fragments but will not bind to epitopes on APP fragments which may be present in the sample; anddetecting binding between the first binding substance and the soluble β
AP and β
AP fragments. - View Dependent Claims (13, 14, 15, 16)
- -amyloid peptide (β
Specification